|
|||||
|
|
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor,in patients with advanced mesothelioma |
|
| Authors: | Zauderer Marjorie G. Alley Evan W. Bendell Johanna Capelletto Enrica Bauer Todd M. Callies Sophie Szpurka Anna M. Kang Suhyun Willard Melinda D. Wacheck Volker Varghese Anna M. |
| Affiliation: | 1.Memorial Sloan Kettering Cancer Center, New York, NY, USA ;3.Cleveland Clinic Florida, Weston, FL, USA ;4.Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN, USA ;5.University of Turin, Torino, TO, Italy ;6.Eli Lilly and Company, Indianapolis, IN, USA ; |
| Abstract: | Investigational New Drugs - BACKGROUND LY3023414 is a selective, ATP competitive inhibitor of class I PI3K isoforms, mTORC1/2 and DNA-PK. A Phase 1 dose escalation, 200 mg twice daily... |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |